Loading clinical trials...
Loading clinical trials...
An Open-label, Multicenter Study to Assess the Safety of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease Who Completed C87035 (NCT00899678) or Who Were Terminated From C87035
Conditions
Interventions
certolizumab pegol
certolizumab pegol
Locations
10
United States
114
Orange, California, United States
111
Aurora, Colorado, United States
103
Atlanta, Georgia, United States
116
Atlanta, Georgia, United States
112
Shreveport, Louisiana, United States
104
Baltimore, Maryland, United States
Start Date
August 1, 2010
Primary Completion Date
November 27, 2017
Completion Date
November 27, 2017
Last Updated
December 17, 2020
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07385131
NCT07383844
Lead Sponsor
UCB Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions